Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers

NCT05154487 is registered in ClinicalTrials.gov with GOG Foundation as lead sponsor.

NCT NCT05154487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05154487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-Positive Endometrioid Endometrial Cancers
Lead sponsor
GOG Foundation
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 11, 2024
Completion date
November 1, 2028
Enrollment
51 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

endometroid endometrial cancer